How androgen levels affect treatment outcomes in advanced prostate cancer
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer
This study is looking at how differences in hormone levels affect the success of treatments for men with castration-resistant prostate cancer, aiming to find out which patients might benefit most from specific therapies based on their genetic makeup.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10912832 on NIH RePORTER |
What this research studies
This research investigates how variations in androgen production, uptake, and metabolism influence the effectiveness of treatments for castration-resistant prostate cancer (CRPC). By analyzing genetic factors related to androgen metabolism, the study aims to identify which patients are more likely to respond to specific therapies. The approach includes evaluating clinical and genetic data from previous trials to develop personalized treatment strategies based on individual genetic profiles. This could help tailor therapies to improve outcomes for patients with CRPC.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who are undergoing treatment.
Not a fit: Patients with prostate cancer that is not castration-resistant or those who are not undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective, personalized treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results in using genetic factors to guide treatment decisions in prostate cancer, indicating that this approach has potential for success.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Halabi, Susan — Duke University
- Study coordinator: Halabi, Susan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.